Effects of platycodins on liver complications of type 2 diabetes.

Molecular medicine reports

PubMedID: 25017203

Luan H, Yang L, Liu L, Liu S, Zhao X, Sui H, Wang J, Wang S. Effects of platycodins on liver complications of type 2 diabetes. Mol Med Rep. 2014;10(3):1597-603.
The aim of the current study was to investigate the therapeutic effects and mechanism of platycodin in liver complications of type 2 diabetes. All rats were randomly divided into two groups: The control group (normal diet) and the model group (a high-fat and high-sugar diet). The model group was injected with 2% streptozocin (25 mg/kg body weight) through the tail vein following 4 weeks of dieting. After a total of 8 weeks of dieting, fasting blood glucose (FBG) and liver function were examined. The high-fat and high-sugar diet was continued in the successful model rats, which were randomly divided into four groups and treated with the following doses of platycodins: The untreated, and 50, 100 and 200 mg/kg body weight/day groups. Platycodins treatment lasted for 12 weeks. Platycodins treatment at a dose of 200 mg/kg body weight/day reduced the FBG, glutamate pyruvate transaminase (GPT), glutamic oxalacetic transaminase, triglycerides, total cholesterol (TC), low-density lipoprotein (LDL) and liver index levels compared with the untreated group (P<0.05), while the high-density lipoprotein levels increased (P<0.05). Furthermore, FBG, GPT, TC and LDL levels were returned to the normal level. This dose also increased the expression of BMP-9 mRNA and BMP-9 protein, and reduced the expression of Smad-4 mRNA and Smad-4 protein. These findings indicate that platycodins can rectify disorders of blood glucose and lipid metabolism, improve liver index and protect liver function in liver complications of type 2 diabetes. The current study suggests that this therapeutic effect is mediated through the BMP-9/Smad-4 pathway.